Answers are grounded in this paper and cite their sources.
Nationwide comparison evaluates HER2 assay variability in breast cancer detection, indicating significant inconsistencies.
PURPOSE: HER2-low breast cancer (BC) has gained clinical relevance due to the efficacy of trastuzumab deruxtecan (T-DXd). However, variability in detecting low HER2 expression may affect patient eligibility. This nationwide study in the Netherlands evaluated the variability in HER2 immunohistochemistry (IHC) assays at low expression levels and compared this to the reported HER2-low rates across pathology laboratories. METHODS: All Dutch pathology laboratories (n=36) were invited. Unstained slides containing dynamic range cell lines and immunohistochemistry calibrators were distributed and processed using each laboratory's routine HER2-IHC protocol and centrally analyzed with AI-based software. The level-of-detection (LOD) was determined with peptide-coated microbeads. Retrospective HER2 data of primary BC cases were extracted from the Dutch Nationwide Pathology Databank (Palga). RESULTS: Overall, 29 out of 36 laboratories were included. The median HER2 expression of the dynamic range cell line was 0.0 (range 0-31,1) in core 0, 0.4 (range 0-62,2) in core 1+ and 4.2 (range 0-65,1) in core 2+. The LOD, evaluated in 20 laboratories, ranged from 17,000 to 41,000 (median 27,000). It showed a significant correlation with HER2 expression intensity in core 1+ of the cell line (p= 0.002), with lower LODs associated with higher expression. However, there was no significant correlation between expression levels in core 1+ of the cell lines and reported HER2 0 or HER2 1+ rates in Palga (p=0.412 and p=0.852 respectively). Similarly, no correlation was found between assay LOD and the reported HER2-low rate (p=0.910). CONCLUSION: HER2 IHC assays show substantial interlaboratory variability at low expression levels. However, this variability does not translate into equivalent differences in reported HER2-low rates in routine clinical practice. A low HER2 expression in cell lines and high LOD, do not show a correlation with reported clinical expression levels. Standardization of analytical and interpretative practices, along with clinical validation of LOD thresholds, are essential.
No takes yet. Share an insight, caveat, or question.
Kain et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: